Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • AI Points to Drug Repurposing Opportunities for Diseases Without Cures

    Oct 31, 2024, 01:00 AM by User Not Found
    Bio-IT World | Harvard scientists have succeeded in using artificial intelligence (AI) to identify promising drug candidates for diseases for which there are no examples of successful treatment. The graph foundation model, known as TxGNN, opens untold opportunities to repurpose drugs for the thousands of diseases afflicting small populations and exacting a huge toll in terms of both economics and human suffering.
    Full story
  • Quris-AI Acquires Nortis

    Oct 30, 2024, 07:21 AM by
    Today, Quris-AI announced the acquisition of Nortis. Nortis' high-quality microphysiology systems (MPS) database and ability to accurately mimic human biology provided a unique value proposition, perfectly aligning with Quris-AI's mission to improve drug safety prediction. Nortis’s Kidney-on-Chip models, which set new standards for in-vitro drug testing and personalized medicine, will be combined with Quris-AI’s advanced machine learning models and patented patient-on-chip system that can predict a real human body’s reaction to drugs and eliminate potentially harmful drug candidates earlier in the drug development process.
    Full story
  • VALANX Biotech and Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development

    Oct 30, 2024, 07:21 AM by
    VALANX Biotech (VALANX) and Fina Biosolutions LLC (FinaBio) today announced the signing of a joint IP and licensing agreement. The companies will launch ClickCRM™, a ready-to-conjugate version of CRM197, an antigenic carrier protein used for making conjugate vaccines. The new product enables the rapid, high-efficiency conjugation of carrier proteins to polysaccharide antigens for the generation of conjugate vaccines.
    Full story
  • Phreesia Achieves Oracle Validated Integration with Oracle Health EHR Expertise for Delivering Proven, Repeatable Integration

    Oct 30, 2024, 07:21 AM by
    Phreesia announced that it has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its integration of the Phreesia platform.
    Full story
  • Sapio Sciences Expands Collaboration With AWS to Advance Science-Aware AI Vision

    Oct 30, 2024, 07:21 AM by
    Sapio Sciences today announced it has strengthened its long-term relationship with Amazon Web Services, Inc. (AWS) through the integration of AWS Bedrock with the Sapio Platform. This integration makes advanced generative AI models readily accessible to scientists and researchers within the same secure AWS environment that already powers Sapio’s Laboratory Information Management System (LIMS) and Electronic Lab Notebook (ELN).
    Full story
  • New 10x Instruments, Merck Acquires Modifi Biosciences, New Immunogenicity Bioanalysis Features, Partnerships, More

    Oct 30, 2024, 01:00 AM by User Not Found
    Bio-IT World | Modifi Biosciences has been acquired by Merck; Sapio Sciences announces the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform; and more.
    Full story
  • Takara Bio Europe Expands Existing Gothenburg Site to Offer Custom Enzyme Manufacturing

    Oct 29, 2024, 08:24 AM by
    Takara Bio Europe has announced the expansion of its Gothenburg facility, with the addition of a custom manufacturing lab. This new facility now offers a comprehensive array of customised molecular biology products, including PCR and qPCR enzymes, servicing the molecular biology needs of academic researchers, diagnostic labs, and biotech companies across EMEA, producing up to 600,000 reactions per week. With these expanded capabilities, customers can expect faster deliveries, personalised service, and real-time access to technical expertise, ensuring projects move forward efficiently while supporting sustainability goals through reduced carbon emissions.
    Full story
  • Coronado Research Limited announce appointment of Professor Jennifer Visser-Rogers as Chief Scientific Officer

    Oct 29, 2024, 08:24 AM by
    Coronado Research announced today that Professor Jennifer Visser-Rogers has been appointed as Chief Scientific Officer.
    Full story
  • Follow the Money: Small Molecule Solutions AI Platform, MIT, Basecamp Research Collaboration, More

    Oct 29, 2024, 01:00 AM by User Not Found
    Bio-IT World | Terray Therapeutics will enhance their integrated AI platform, tNova, which identifies and optimizes novel small molecule solutions to the most complex problems; Basecamp Research, in collaboration with the laboratory of Dr. David R. Liu at the Broad Institute of MIT and Harvard, plans to advance their data collection and strengthen their AI capabilities; and more.
    Full story
  • CluePoints Appoints Richard Young as Chief Strategy Officer

    Oct 28, 2024, 08:04 AM by
    RBQM innovator CluePoints has today announced that Richard Young has been appointed as its new Chief Strategy Officer. With 30 years of experience in clinical data management, Richard is an expert in his field.
    Full story
  • Sapio Sciences Adds Electronic Batch Record Functionality to Unified GMP LIMS Solution

    Oct 25, 2024, 08:52 AM by
    Sapio Sciences today announced the addition of new Electronic Batch Record (EBR) functionality to Sapio GMP (Good Manufacturing Practice) LIMS. Designed for laboratories that must comply with GMP, 21 CFR 11, and EU Annex 11 standards, the Sapio GMP LIMS offers unparalleled flexibility to meet compliance standards in biotechnology, pharmaceuticals, clinical research and diagnostics, food and beverage, chemicals, and environmental testing.
    Full story
  • AI Is Nothing Without An AI-Ready Data Strategy

    Oct 25, 2024, 01:00 AM by User Not Found
    Bio-IT World | Applied artificial intelligence (AI) is already transforming drug discovery research and development, accelerating the journey from lab to lifesaving therapies, and both the reality and the hype are very well known. Less obvious—almost 90% of the iceberg—is the critical role played by data.
    Full story
  • CluePoints Wins Growth Award at BVA Private Equity Awards

    Oct 24, 2024, 08:08 AM by
    CluePoints, provider of leading statistical and AI-driven software solutions, has been recognized for its impressive growth at the BVA Private Equity Awards.
    Full story
  • Cleveland Clinic Researchers Find Hope in Immune Cells’ Reaction to Immunotherapy

    Oct 23, 2024, 13:43 PM by User Not Found
    Bio-IT World | There is much we still don’t know about the relationship between immune cells and cancer cells and how they interact and influence each other over the course of immune activating cancer therapies. Researchers at Cleveland Clinic are exploring these relationships and reported their results last month in Nature Medicine.
    Full story
  • Biopharma PEG Provides Advanced PEG Solutions for Drug Development

    Oct 23, 2024, 08:15 AM by
    Biopharma PEG has launched a range of polyethylene glycol (PEG) products for PEGylation, improving drug efficacy. With over 40 approved PEGylated drugs, interest in monodispersed PEGs is growing, as seen with Movantik. Biopharma PEG is dedicated to supporting PEGylated drug development.
    Full story
  • DNAnexus Strengthens Leadership Team to Drive Ongoing Product Innovation and Commercial Growth

    Oct 23, 2024, 08:15 AM by
    DNAnexus announced the appointment of Nupura Kolwalkar as chief product officer and Bill Madigan as chief commercial officer.
    Full story
  • Ellison Institute of Technology Los Angeles Accelerates Cancer Research with Sapio LIMS

    Oct 23, 2024, 08:14 AM by
    Sapio Sciences, the science-aware™ lab informatics platform, today announced that the Ellison Institute of Technology Los Angeles (EIT Los Angeles), a leading interdisciplinary research center focused on cancer and global health, has successfully deployed Sapio Sciences' Laboratory Information Management System (LIMS) to streamline its complex research operations and accelerate scientific discovery.
    Full story
  • KLAS Research Recognizes Proscia For Improving Patient Outcomes

    Oct 23, 2024, 08:14 AM by
    Proscia was named to KLAS Research’s 2024 Emerging Solutions Top 20 list of technologies best positioned to impact the Quadruple Aim of Healthcare. Its Concentriq software platform was selected by healthcare leaders across the United States for improving patient outcomes. Awardees were celebrated at the HLTH USA event in Las Vegas, Nevada.
    Full story
  • Optibrium Demonstrates Superior Molecular Docking Method for Small Molecules and Macrocycles

    Oct 23, 2024, 08:14 AM by
    Optibrium, a leading developer of software and AI solutions for molecular design today announced the publication of a peer-reviewed study in the Journal of Computer-Aided Molecular Design, ‘Structure-Based Pose Prediction: Non-cognate Docking Extended to Macrocylic Ligands’. The paper demonstrates that Surflex-Dock can accurately predict the binding conformation and orientation (pose) of unknown (non-cognate) ligands, including macrocycles.
    Full story
  • Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024

    Oct 22, 2024, 08:27 AM by
    Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional breakthrough research from collaborators advancing proteomic discovery at scale
    Full story
  • «
  • 21
  • 22
  • 23 (current)
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy